Rajaratnam Assigned To Mass. Prison

Nov 3 2011 | 9:17am ET

It seems two of the biggest hedge fund fraudsters in history won't be neighbors in jail, after all.

Despite a recommendation from the judge in the case that he be sent to a Bureau of Prisons medical center in Butner, N.C., Galleon Group founder Raj Rajaratnam has been assigned to another prison medical center somewhat closer to home, about 40 miles outside Boston. Rajaratnam, who was sentenced last month to 11 years in prison, has been ordered to report to the Federal Medical Center Devens in Ayer, Mass., on Dec. 5, Bloomberg News reports.

It is not clear why the Bureau of Prisons picked Devens over Butner. Rajaratnam has a whole host of medical ailments, highlighted by severe diabetes. His lawyers say he is likely to require a kidney transplant—something 15 Devens inmates have had over the past seven years.

Had the Bureau accepted U.S. District Judge Richard Holwell's recommendation, made at the urging of Rajaratnam, the Galleon fraudster would have shared a prison complex with Bernard Madoff, who is serving his 150-year sentence for running a $65 billion Ponzi scheme at Butner.


In Depth

Change In 'Accredited Investor' Definition Could Hurt Crowdfunding Space

Jul 25 2014 | 8:14am ET

The Securities and Exchange Commission is considering changes to its 30-year-old...

Lifestyle

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Guest Contributor

The Truth About Track Record Portability

Jul 24 2014 | 5:55am ET

The number of private funds converting to mutual funds has increased significantly...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note